BD OptiBuildTM BV421 Rat Anti-Human CD366 (TIM-3)

Description

Flow cytometric analysis of CD366 TIM-3 expression on peripheral blood leucocytes. Whole blood was treated with 1 BD Pharm Lyse Lysing Solution Cat. No. 555899 to remove erythrocytes. The remaining leucocytes were washed and then costained with PE Mouse Anti-Human CD56 Cat. No. 555516 or 561903 and either BD Horizon BV421 Rat IgG2a, kappa Isotype Control Cat. No. 562602; Left Plots or BD OptiBuild BV421 Rat Anti-Human CD366 TIM-3 Cat. No. 747962; Right Plots at 0.5 mug/test. Left Plots: The pseudocolor dot plots showing the coexpression of CD366 TIM-3 or Ig Isotype control staining versus side-scattered light signals were derived from gated events with the forward and side light scattering characteristics of viable leucocyte populations. Right Plots: The pseudocolor dot plots showing the coexpression of CD366 TIM-3 or Ig Isotype control staining versus CD56 were derived from gated events with the forward and side light scattering characteristics of viable lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot. Flow cytometric analysis of CD366 TIM-3 expression on peripheral blood leucocytes. Whole blood was treated with 1 BD Pharm Lyse Lysing Solution Cat. No. 555899 to remove erythrocytes. The remaining leucocytes were washed and then costained with PE Mouse Anti-Human CD56 Cat. No. 555516 or 561903 and either BD Horizon BV421 Rat IgG2a, kappa Isotype Control Cat. No. 562602; Left Plots or BD OptiBuild BV421 Rat Anti-Human CD366 TIM-3 Cat. No. 747962; Right Plots at 0.5 mug/test. Left Plots: The pseudocolor dot plots showing the coexpression of CD366 TIM-3 or Ig Isotype control staining versus side-scattered light signals were derived from gated events with the forward and side light scattering characteristics of viable leucocyte populations. Right Plots: The pseudocolor dot plots showing the coexpression of CD366 TIM-3 or Ig Isotype control staining versus CD56 were derived from gated events with the forward and side light scattering characteristics of viable lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot. Flow cytometric analysis of CD366 TIM-3 expression on peripheral blood leucocytes. Whole blood was treated with 1 BD Pharm Lyse Lysing Solution Cat. No. 555899 to remove erythrocytes. The remaining leucocytes were washed and then costained with PE Mouse Anti-Human CD56 Cat. No. 555516 or 561903 and either BD Horizon BV421 Rat IgG2a, kappa Isotype Control Cat. No. 562602; Left Plots or BD OptiBuild BV421 Rat Anti-Human CD366 TIM-3 Cat. No. 747962; Right Plots at 0.5 mug/test. Left Plots: The pseudocolor dot plots showing the coexpression of CD366 TIM-3 or Ig Isotype control staining versus side-scattered light signals were derived from gated events with the forward and side light scattering characteristics of viable leucocyte populations. Right Plots: The pseudocolor dot plots showing the coexpression of CD366 TIM-3 or Ig Isotype control staining versus CD56 were derived from gated events with the forward and side light scattering characteristics of viable lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot. Show More Flow cytometric analysis of CD366 TIM-3 expression on peripheral blood leucocytes. Whole blood was treated with 1 BD Pharm Lyse Lysing Solution Cat. No. 555899 to remove erythrocytes. The remaining leucocytes were washed and then costained with PE Mouse Anti-Human CD56 Cat. No. 555516 or 561903 and either BD Horizon BV421 Rat IgG2a, kappa Isotype Control Cat. No. 562602; Left Plots or BD OptiBuild BV421 Rat Anti-Human CD366 TIM-3 Cat. No. 747962; Right Plots at 0.5 mug/test. Left Plots: The pseudocolor dot plots showing the coexpression of CD366 TIM-3 or Ig Isotype control staining versus side-scattered light signals were derived from gated events with the forward and side light scattering characteristics of viable leucocyte populations. Right Plots: The pseudocolor dot plots showing the coexpression of CD366 TIM-3 or Ig Isotype control staining versus CD56 were derived from gated events with the forward and side light scattering characteristics of viable lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot. Show More Flow cytometric analysis of CD366 TIM-3 expression on peripheral blood leucocytes. Whole blood was treated with 1 BD Pharm Lyse Lysing Solution Cat. No. 555899 to remove erythrocytes. The remaining leucocytes were washed and then costained with PE Mouse Anti-Human CD56 Cat. No. 555516 or 561903 and either BD Horizon BV421 Rat IgG2a, kappa Isotype Control Cat. No. 562602; Left Plots or BD OptiBuild BV421 Rat Anti-Human CD366 TIM-3 Cat. No. 747962; Right Plots at 0.5 mug/test. Left Plots: The pseudocolor dot plots showing the coexpression of CD366 TIM-3 or Ig Isotype control staining versus side-scattered light signals were derived from gated events with the forward and side light scattering characteristics of viable leucocyte populations. Right Plots: The pseudocolor dot plots showing the coexpression of CD366 TIM-3 or Ig Isotype control staining versus CD56 were derived from gated events with the forward and side light scattering characteristics of viable lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot. Flow cytometric analysis of CD366 TIM-3 expression on peripheral blood leucocytes. Whole blood was treated with 1 BD Pharm Lyse Lysing Solution Cat. No. 555899 to remove erythrocytes. The remaining leucocytes were washed and then costained with PE Mouse Anti-Human CD56 Cat. No. 555516 or 561903 and either BD Horizon BV421 Rat IgG2a, kappa Isotype Control Cat. No. 562602; Left Plots or BD OptiBuild BV421 Rat Anti-Human CD366 TIM-3 Cat. No. 747962; Right Plots at 0.5 mug/test. Left Plots: The pseudocolor dot plots showing the coexpression of CD366 TIM-3 or Ig Isotype control staining versus side-scattered light signals were derived from gated events with the forward and side light scattering characteristics of viable leucocyte populations. Right Plots: The pseudocolor dot plots showing the coexpression of CD366 TIM-3 or Ig Isotype control staining versus CD56 were derived from gated events with the forward and side light scattering characteristics of viable lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. The above is qualification data only and does not represent a specific OptiBuild lot.